Additional file 1 of Opioid exposure during pregnancy and the risk of congenital malformation: a meta-analysis of cohort studies

Additional file 1 Table S1. Search terms. Table S2. Summary of risk of bias assessment using ROBINS-I tool. Fig. S1. Eggers’s test of studies examining the association between opioids exposure and the risk of congenital malformations. Fig. S2. Forest plot of association between opioid exposure and major congenital malformation. Fig. S3. Forest plot of association between opioid exposure and central nervous system malformation. Fig. S4. Forest plot of association between opioid exposure and limb malformation. Fig. S5. Forest plot of assoxiation between opioid exposure and cardiovascular malformation. Fig. S6. Forest plot of association between opioid exposure and gastrointestinal malformation. Fig. S7. Forest plot of association between opioid exposure and ear, face, and neck malformation. Fig. S8. Forest plot of association between opioid exposure and respiratory malformation. Fig. S9. Forest plot of association between opioid exposure and musculoskeletal malformation. Fig. S10. Forest plot of association between opioid exposure and urogenital malformation. Fig. S11. Forest plot of association between opioid exposure and orofacial malformation. Fig. S12. Forest plot of association between opioid exposure and neural tube defects. Fig. S13. Forest plot of association between opioid exposure and gastroschisis. Fig. S14. Forest plot of association between opioid exposure and clubfoot. Fig. S15. Meta-regression according to the year of publication. Fig. S16. Forest plot of subgroup analysis of exposed period. Fig. S17. Forest plot of subgroup analysis of indication. Fig. S18: Forest plot of subgroup analysis of adjusted for confounders. Fig. S19. Forest plot of subgroup analysis of risk of bias assessment

DataSheet_1_Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study.docx

BackgroundImmune checkpoint inhibitors (ICIs) are associated with different immune-related adverse events (irAEs), but there is limited evidence regarding the association between urinary incontinence and ICIs.MethodsWe described the case of a patient experiencing urinary incontinence who later experienced a series of irAEs such as myocarditis, myositis, and neurologic diseases while on ICI treatment in our hospital. In addition, we queried the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from the third quarter of 2010 to the third quarter of 2020 to perform a retrospective study to characterize the clinical features of urinary incontinence associated with ICIs.ResultIn the FAERS study, 59 cases of ICI-related urinary incontinence were retrieved, and approximately 32.2% of the cases were fatal. Combination therapy with nervous system drugs and age >80 years old were the significant risk factors for fatal outcomes. Among these cases of ICI-related urinary incontinence, 40.7% (n = 24) occurred concomitantly with other adverse events, especially, neurological (fifteen cases), cardiovascular (seven cases), musculoskeletal (six cases), and urological disorders (five cases). Five cases had an overlapping syndrome similar to our case report, including one case of myasthenia gravis with myocarditis and another of myasthenic syndrome with polymyositis.ConclusionICI-related urinary incontinence might be a signal of fatal neuromuscular irAEs, especially when it occurs concomitantly with ICI-associated neuromuscular–cardiovascular syndrome. Clinicians should be aware of the occurrence of urinary incontinence to identify potentially lethal irAEs in the early phase.</p